查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602171

治療藥物監測市場：按產品、技術、藥物類別和最終用戶 - 2025-2030 年全球預測

Therapeutic Drug Monitoring Market by Product (Consumables, Data Management Services, Equipment), Technology (Chromatography-MS, Immunoassays, Proteomic Technologies), Drug Class, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年治療藥物監測市場價值為37.9億美元，預計到2024年將達到43.8億美元，複合年成長率為16.11%，到2030年將達到107.8億美元。

治療藥物監測 (TDM) 涉及測量血流中的藥物濃度，以最佳化劑量並最大限度地提高治療效果，同時最大限度地降低毒性。由於患者在藥物吸收、分佈、代謝和排泄方面存在差異，因此需要個別化給藥方案，因此需要 TDM。 TDM的應用主要包括治療範圍較窄的藥物，如抗驚厥藥、抗生素和免疫抑制劑，在個人化醫療中至關重要，可確保有效治療，同時最大限度地減少副作用。最終使用範圍主要延伸到醫院、實驗室和臨床環境[藥物動力學單位]，我們正在積極努力提高治療的有效性和安全性。 TDM 市場的成長受到慢性病盛行率上升、藥物基因組學進步以及對個人化醫療日益關注等因素的影響，但也受到檢測成本上升、嚴格的法律規範以及對高技能專業人員的需求等問題的影響。此外，TDM 還提供了潛在的機會，可以透過就地檢驗的創新和預測性監測人工智慧的整合，為即時藥物監測和改善患者治療結果鋪平道路。為了利用這些機會，相關人員正在投資研發以創建具有成本效益的 TDM 解決方案，與生物技術公司和醫療機構建立策略夥伴關係，並擴大覆蓋範圍和適應性。市場限制包括技術限制和低度開發地區缺乏認知，但非侵入性採樣和快速診斷技術的進步有可能顯著克服這些挑戰。最有前景的技術創新領域包括開發攜帶式、易於使用的監控設備和增強的資料分析能力，以提供更準確和可操作的見解。總體而言，對技術創新、可負擔性和以患者為中心的解決方案的策略重點對於持續的市場成長和抓住動態治療藥物監測領域的新機會至關重要。

主要市場統計
基準年[2023] 37.9億美元
預測年份 [2024] 43.8億美元
預測年份 [2030] 107.8億美元
複合年成長率（%） 16.11%

市場動態：快速發展的治療藥物監測市場的關鍵市場洞察

供需的動態交互作用正在改變治療藥物監測市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 個人化醫療需求不斷成長
    • 在各個治療領域更常採用治療藥物監測
    • 在固態器官移植患者的使用和重要性不斷增加
  • 市場限制因素
    • 報銷政策不完善
    • 需要昂貴的資本投資
  • 市場機會
    • 開發中國家治療藥物監測的未來前景
    • 免疫檢測和其他治療藥物監測技術的進展
  • 市場挑戰
    • 臨床問題和熟練實驗室技術人員的短缺

波特五力：駕馭治療藥物監測市場的策略工具

波特的五力架構是了解治療藥物監測市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解治療藥物監測市場的外部影響

外部宏觀環境因素在塑造治療藥物監測市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解治療藥物監測市場的競爭狀況

對治療藥物監測市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣治療監測市場供應商的績效評估

FPNV定位矩陣是評估治療藥物監測市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 對個人化醫療的需求不斷增加
      • 在各個治療領域更常採用治療藥物監測
      • 在固態器官移植患者的使用和重要性不斷增加
    • 抑制因素
      • 退款政策不佳
      • 需要大量資本投資
    • 機會
      • 開發中國家治療藥物監測的未來前景
      • 免疫檢測和其他治療藥物監測技術的進展
    • 任務
      • 臨床挑戰和熟練實驗室技術人員的短缺
  • 市場區隔分析
    • 產品：對高效藥物管理的資料管理服務的需求不斷成長
    • 最終用戶：醫院的需求不斷成長，準確的藥品管理至關重要
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境
  • 客戶客製化

第6章治療藥物監測市場：依產品

  • 消耗品
  • 資料管理服務
  • 裝置
    • 層析法和質譜檢測器
    • 臨床生化分析儀
    • 免疫檢測分析儀

第7章治療藥物監測市場：依技術分類

  • 層析法-MS
    • GC-MS
    • LC-MS
  • 免疫檢測
    • 化學冷光免疫檢測
    • 比色免疫檢測
    • 螢光免疫分析法
    • 免疫檢測
  • 蛋白質體技術

第8章按藥物類別分類的治療藥物監測市場

  • 抗心律不整藥物
  • 抗生素
  • 抗癲癇藥
  • 支氣管擴張劑
  • 免疫抑制藥物
  • 精神藥物

第9章 治療藥物監測市場：依最終使用者分類

  • 醫院實驗室
  • 私人實驗室

第10章美洲治療藥物監測市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區治療藥物監測市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的治療藥物監測市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Capitainer 宣布與阿斯特捷利康建立合作關係。
    • Novo Holdings 投資蛋白質體學技術公司 Evosep。
    • AegirBio AB 已與 Atlas Special Opportunities, LLC 簽署協議，發行 5,500 萬瑞典克朗帶認股權證的可轉換債券，以加強對 TDM、唾液樣本採集等領域的投資。
    • 用於治療藥物監測分析的臨床 LC-MS 方法。
    • Boditech Med取得4個TDM產品的出口許可。
    • Pace 檢測戴奧辛和二苯並呋喃的 GC-MS/MS 技術已獲得 EPA核准。
    • Bio-Rad 擴展了其用於生物分析和藥物監測的抗個體遺傳型抗體系列。
    • Beckman Coulter 和 Saladax Biomedical 在抗精神病藥物監測方面合作。
    • Ampersand Capital Partners 投資了領先的 SIFT-MS解決方案供應商Syft Technologies。

公司名單

  • apDia Group
  • Cambridge Life Sciences Limited
  • Danaher Corporation
  • ARK Diagnostics, Inc.
  • Assay Genie
  • DiaSorin SpA
  • Merck KGaA
  • Grifols, SA
  • Siemens Healthineers AG
  • Cardinal Health, Inc.
  • Pfizer Inc.
  • DiaSystem Scandinavia AB
  • R-Biopharm AG
  • Bio-Rad Laboratories, Inc.
  • Krishgen Biosystems
  • HU Group Holdings, Inc.
  • Buhlmann Laboratories AG
  • Myriad Genetics, Inc.
  • Theradiag SA
  • Randox Laboratories, Ltd.
  • Thermo Fisher Scientific, Inc.
  • Tecan Trading AG
  • OneCare Media, LLC
  • Chromsystems Instruments & Chemicals GmbH
  • Agilent Technologies, Inc.
  • Eagle Biosciences, Inc.
  • Svar Life Science AB
  • Sekisui Chemical Co Ltd.
  • Neoteryx, LLC by Trajan Group
  • Veolia Group
  • bioMerieux SA
  • ARUP Laboratories
  • Abbott Laboratories
  • F. Hoffmann-La Roche AG
  • Exagen Inc.
Product Code: MRR-A77F2EE7AB43

The Therapeutic Drug Monitoring Market was valued at USD 3.79 billion in 2023, expected to reach USD 4.38 billion in 2024, and is projected to grow at a CAGR of 16.11%, to USD 10.78 billion by 2030.

Therapeutic Drug Monitoring (TDM) involves measuring drug concentrations in the bloodstream to optimize dosage and maximize therapeutic efficacy while minimizing toxicity. The necessity of TDM arises from the need to individualize medication regimens due to patient variability in drug absorption, distribution, metabolism, and excretion. Applications of TDM primarily include drugs with narrow therapeutic ranges, such as anticonvulsants, antibiotics, and immunosuppressants, and are crucial in personalized medicine, ensuring effective treatment while reducing adverse effects. The end-use scope primarily extends to hospitals, laboratories, and clinical settings [pharmacokinetic units], actively engaged in increasing treatment efficacy and safety. The market growth of TDM is influenced by factors such as the rising prevalence of chronic diseases, advancements in pharmacogenomics, and an increased focus on personalized medicine; however, challenges such as the high cost of testing, strict regulatory frameworks, and the need for skilled professionals could hamper growth. Moreover, TDM presents potential opportunities with innovations in point-of-care testing and the integration of AI for predictive monitoring, creating avenues for real-time drug monitoring and improving patient outcomes. To leverage these opportunities, stakeholders should invest in research and development to create cost-effective TDM solutions, fostering strategic partnerships with biotech firms and healthcare facilities to broaden their reach and adaptability. While market limitations include technological limitations and a lack of awareness in undeveloped regions, advancements in non-invasive sampling and rapid diagnostic techniques could significantly surmount these challenges. The most promising areas for innovation encompass developing portable and user-friendly monitoring devices and enhancing data analytics capabilities to deliver more precise and actionable insights. Overall, a strategic focus on innovation, affordability, and patient-centric solutions would be paramount for sustained market growth and capturing emerging opportunities in the dynamic field of Therapeutic Drug Monitoring.

KEY MARKET STATISTICS
Base Year [2023] USD 3.79 billion
Estimated Year [2024] USD 4.38 billion
Forecast Year [2030] USD 10.78 billion
CAGR (%) 16.11%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Therapeutic Drug Monitoring Market

The Therapeutic Drug Monitoring Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increased Demand for Personalized Medicine
    • Rising Adoption of Therapeutic Drug Monitoring Across Various Therapeutic Fields
    • Growing Use and Importance in Patients with Solid Organ Transplantation
  • Market Restraints
    • Inadequate Reimbursement Policies
    • Need of High Capital Investments
  • Market Opportunities
    • Future Perspectives of Therapeutic Drug Monitoring in Developing Nations
    • Developments in Immunoassay and Other Therapeutic Drug Monitoring Technologies
  • Market Challenges
    • Clinical Challenges and Limited Availability of Skilled Laboratory Technicians

Porter's Five Forces: A Strategic Tool for Navigating the Therapeutic Drug Monitoring Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Therapeutic Drug Monitoring Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Therapeutic Drug Monitoring Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Therapeutic Drug Monitoring Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Therapeutic Drug Monitoring Market

A detailed market share analysis in the Therapeutic Drug Monitoring Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Therapeutic Drug Monitoring Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Therapeutic Drug Monitoring Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Therapeutic Drug Monitoring Market, highlighting leading vendors and their innovative profiles. These include apDia Group, Cambridge Life Sciences Limited, Danaher Corporation, ARK Diagnostics, Inc., Assay Genie, DiaSorin SpA, Merck KGaA, Grifols, S.A., Siemens Healthineers AG, Cardinal Health, Inc., Pfizer Inc., DiaSystem Scandinavia AB, R-Biopharm AG, Bio-Rad Laboratories, Inc., Krishgen Biosystems, H.U. Group Holdings, Inc., Buhlmann Laboratories AG, Myriad Genetics, Inc., Theradiag SA, Randox Laboratories, Ltd., Thermo Fisher Scientific, Inc., Tecan Trading AG, OneCare Media, LLC, Chromsystems Instruments & Chemicals GmbH, Agilent Technologies, Inc., Eagle Biosciences, Inc., Svar Life Science AB, Sekisui Chemical Co Ltd., Neoteryx, LLC by Trajan Group, Veolia Group, bioMerieux SA, ARUP Laboratories, Abbott Laboratories, F. Hoffmann-La Roche AG, and Exagen Inc..

Market Segmentation & Coverage

This research report categorizes the Therapeutic Drug Monitoring Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Consumables, Data Management Services, and Equipment. The Equipment is further studied across Chromatography & MS Detectors, Clinical Chemistry Analyzers, and Immunoassay Analyzers.
  • Based on Technology, market is studied across Chromatography-MS, Immunoassays, and Proteomic Technologies. The Chromatography-MS is further studied across GC-MS and LC-MS. The Immunoassays is further studied across Chemiluminescence Immunoassays, Colorimetric Immunoassays, Fluorescence Immunoassays, and Radioimmunoassays.
  • Based on Drug Class, market is studied across Antiarrhythmic Drugs, Antibiotic Drugs, Antiepileptic Drugs, Bronchodilator Drugs, Immunosuppressant Drugs, and Psychoactive Drugs.
  • Based on End-User, market is studied across Hospital Labs and Private Labs.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increased Demand for Personalized Medicine
      • 5.1.1.2. Rising Adoption of Therapeutic Drug Monitoring Across Various Therapeutic Fields
      • 5.1.1.3. Growing Use and Importance in Patients with Solid Organ Transplantation
    • 5.1.2. Restraints
      • 5.1.2.1. Inadequate Reimbursement Policies
      • 5.1.2.2. Need of High Capital Investments
    • 5.1.3. Opportunities
      • 5.1.3.1. Future Perspectives of Therapeutic Drug Monitoring in Developing Nations
      • 5.1.3.2. Developments in Immunoassay and Other Therapeutic Drug Monitoring Technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Clinical Challenges and Limited Availability of Skilled Laboratory Technicians
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Rising demand for data management services for efficient drug management
    • 5.2.2. End-User: Increasing demand from hospitals where accurate drug management is essential
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Therapeutic Drug Monitoring Market, by Product

  • 6.1. Introduction
  • 6.2. Consumables
  • 6.3. Data Management Services
  • 6.4. Equipment
    • 6.4.1. Chromatography & MS Detectors
    • 6.4.2. Clinical Chemistry Analyzers
    • 6.4.3. Immunoassay Analyzers

7. Therapeutic Drug Monitoring Market, by Technology

  • 7.1. Introduction
  • 7.2. Chromatography-MS
    • 7.2.1. GC-MS
    • 7.2.2. LC-MS
  • 7.3. Immunoassays
    • 7.3.1. Chemiluminescence Immunoassays
    • 7.3.2. Colorimetric Immunoassays
    • 7.3.3. Fluorescence Immunoassays
    • 7.3.4. Radioimmunoassays
  • 7.4. Proteomic Technologies

8. Therapeutic Drug Monitoring Market, by Drug Class

  • 8.1. Introduction
  • 8.2. Antiarrhythmic Drugs
  • 8.3. Antibiotic Drugs
  • 8.4. Antiepileptic Drugs
  • 8.5. Bronchodilator Drugs
  • 8.6. Immunosuppressant Drugs
  • 8.7. Psychoactive Drugs

9. Therapeutic Drug Monitoring Market, by End-User

  • 9.1. Introduction
  • 9.2. Hospital Labs
  • 9.3. Private Labs

10. Americas Therapeutic Drug Monitoring Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Therapeutic Drug Monitoring Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Therapeutic Drug Monitoring Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Capitainer announces collaboration with AstraZeneca.
    • 13.3.2. Novo Holdings invests in proteomics technology company, Evosep.
    • 13.3.3. AegirBio AB enters into an agreement with Atlas Special Opportunities, LLC regarding convertible bonds of SEK 55 million with attached warrants to intensify investments in i.a. TDM and saliva sampling.
    • 13.3.4. Clinical LC-MS methods for therapeutic drug monitoring analysis.
    • 13.3.5. Boditech Med has obtained the export license of four TDM products.
    • 13.3.6. Pace Obtains EPA Approval on Method for Detecting Dioxins and Dibenzofurans Through GC-MS/MS Technology.
    • 13.3.7. Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Bioanalysis and Drug Monitoring.
    • 13.3.8. Beckman Coulter and Saladax Biomedical Team Up on Antipsychotic Therapeutic Drug Monitoring.
    • 13.3.9. Ampersand Capital Partners Invests in Syft Technologies, Leading SIFT-MS Solutions Provider.

Companies Mentioned

  • 1. apDia Group
  • 2. Cambridge Life Sciences Limited
  • 3. Danaher Corporation
  • 4. ARK Diagnostics, Inc.
  • 5. Assay Genie
  • 6. DiaSorin SpA
  • 7. Merck KGaA
  • 8. Grifols, S.A.
  • 9. Siemens Healthineers AG
  • 10. Cardinal Health, Inc.
  • 11. Pfizer Inc.
  • 12. DiaSystem Scandinavia AB
  • 13. R-Biopharm AG
  • 14. Bio-Rad Laboratories, Inc.
  • 15. Krishgen Biosystems
  • 16. H.U. Group Holdings, Inc.
  • 17. Buhlmann Laboratories AG
  • 18. Myriad Genetics, Inc.
  • 19. Theradiag SA
  • 20. Randox Laboratories, Ltd.
  • 21. Thermo Fisher Scientific, Inc.
  • 22. Tecan Trading AG
  • 23. OneCare Media, LLC
  • 24. Chromsystems Instruments & Chemicals GmbH
  • 25. Agilent Technologies, Inc.
  • 26. Eagle Biosciences, Inc.
  • 27. Svar Life Science AB
  • 28. Sekisui Chemical Co Ltd.
  • 29. Neoteryx, LLC by Trajan Group
  • 30. Veolia Group
  • 31. bioMerieux SA
  • 32. ARUP Laboratories
  • 33. Abbott Laboratories
  • 34. F. Hoffmann-La Roche AG
  • 35. Exagen Inc.

LIST OF FIGURES

  • FIGURE 1. THERAPEUTIC DRUG MONITORING MARKET RESEARCH PROCESS
  • FIGURE 2. THERAPEUTIC DRUG MONITORING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. THERAPEUTIC DRUG MONITORING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. THERAPEUTIC DRUG MONITORING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. THERAPEUTIC DRUG MONITORING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. THERAPEUTIC DRUG MONITORING MARKET DYNAMICS
  • TABLE 7. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DATA MANAGEMENT SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY & MS DETECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY GC-MS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY LC-MS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COLORIMETRIC IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY FLUORESCENCE IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY RADIOIMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PROTEOMIC TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIARRHYTHMIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIBIOTIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIEPILEPTIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY BRONCHODILATOR DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANT DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PSYCHOACTIVE DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HOSPITAL LABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRIVATE LABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 151. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 165. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. VIETNAM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 187. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 194. EGYPT THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 201. FINLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 208. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 215. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 222. ISRAEL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 229. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 236. NETHERLANDS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 243. NIGERIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 250. NORWAY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 257. POLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 264. QATAR THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 271. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 278. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 285. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 291. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 292. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 298. SWEDEN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 299. SWEDEN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 300. SWITZERLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 301. SWITZERLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 305. SWITZERLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 306. SWITZERLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 307. TURKEY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 308. TURKEY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 311. TURKEY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 312. TURKEY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 313. TURKEY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 314. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 315. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 316. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED KINGDOM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED KINGDOM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED KINGDOM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED KINGDOM THERAPEUTIC DRUG MONITORING MARKET SIZ